This article is more than 5 years old. Information may no longer be current.

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

Issue: November/December 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1, interventional, open-label study to determine the largest safe dose of chimeric T cells for patients with sarcoma, and to determine the safety of providing HER2-CD28 T cells after lymphodepleting chemotherapy.